MDACC Study No:2012-0976 ( NCT No: NCT01767454)
Title:Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK
Inhibitor Trametinib in Combination with Ipilimumab for
V600E/K Mutation Positive Metastatic or Unresectable
Principal Investigator:Sapna P. Patel
Treatment Agent:GSK1120212 ; GSK2118436; Ipilimumab
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination of dabrafenib and ipilimumab that can be given with or
without trametinib to patients with metastatic melanoma that is positive for
the BRAF mutation. Mutations are abnormal changes in the DNA, the genetic
material in the cells of the body.

Dabrafenib is designed to block the mutated BRAF protein. By blocking the
protein, the drug may slow the growth of or kill cancer cells that have the

Trametinib is designed to block certain proteins that cause cancer cells to
grow and multiply. This may cause the cancer cells to die, especially in cells
with BRAF mutation.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
The drug blocks a molecule that is believed to shut down the part of the immune
system that attacks cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:GSK1120212
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Glaxo Smith-Kline
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults